GlassScriptPhysician profile
Meraj Baig
NPI 1699259036
$12,401.98
in general payments reported to CMS, 2019-2025
36 companies · $2,694 in 2025
The $2,694 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,352 · 2022: $2,257 · 2023: $2,101 · 2024: $2,997 · 2025: $2,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,792.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,706.78 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,181.44 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $1,162.44 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $788.86 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $762.38 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $724.31 | 2021-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $614.32 | 2021-2025 | Caplyta |
| Almatica Pharma LLC | $553.26 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $551.36 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $494.00 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $491.92 | 2021-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $449.22 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $431.75 | 2022-2025 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $407.71 | 2021-2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $313.96 | 2021-2025 | Trintellix |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meraj Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.